(CEFTRIAXONE 1000 MG TAZOBACTUM 125 MG)
Packing: – Vial
Ceftriaxone interferes with the biosynthesis of the peptidoglycan component of the bacterial cell way by binding to and inactivating penicllin-binding proteins (PBPs). Tazobactam is a penicillanic acid sulfone derivative with lactamase inhibitory properties. It enhances the activity of lactam antibacterials against lactamase-producing bacteria.
Distribution: – Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier.
Tazobactam: About 30% bound to plasma proteins; widely distributed to tissues and body fluids. Excretion: – Ceftriaxone:
Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug
Pharmacodynamics: – Ceftriaxone is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms by inhibiting bacterial cell wall synthesis. Ceftriaxone inhibits transpeptidase & thus prevents cross linking of bacterial cell wall. Transpeptidase & associated proteins constitute various types of specific binding proteins which have affinity for cephalosporins like Ceftriaxone.
• Lower respiratory tract infections and community-acquired pneumonia.
• Acute bacterial otitis media.
• Skin and skin structure infections.
• Urinary tract infections. Uncomplicated gonorrhea.
• Pelvic inflammatory disease.
• Bacterial septicemia .
• Intra-abdominal infections.
• Bacterial Meningitis.